Nyxoah’s Q2 Losses Persist Despite Revenue Growth

Forward-Looking Analysis

Analyst consensus for Nyxoah’s second quarter of 2026 indicates continued financial challenges despite strategic market expansions. Projected revenue for the quarter is estimated at approximately $7.2 million, reflecting a moderate year-over-year increase driven by heightened adoption of hypoglossal nerve stimulation devices in European and emerging markets. However, profitability remains elusive, with net income forecasts pointing to a significant deficit. Net profit is expected to land around $-14.5 million, slightly better than previous quarters but still indicative of heavy operational burn rates associated with clinical trials and market penetration efforts.

Earnings per share (EPS) estimates center on $-0.35, representing a marginal improvement from the prior quarter’s loss. This improvement is primarily attributed to slight efficiencies in cost of goods sold rather than top-line surge. Major financial institutions, including Jefferies and Needham, have maintained Hold ratings on the stock, citing the long path to GAAP profitability. While some analysts have raised price targets to $18 based on long-term addressable market growth, they caution that near-term earnings will likely disappoint due to non-recurring R&D expenditures. No upgrades to Buy ratings have been issued, and the prevailing sentiment suggests investors should expect volatility as the company navigates the gap between revenue growth and operational expense management. The focus remains on cash runway extension and successful regulatory approvals in new territories rather than immediate bottom-line gains.

Historical Performance Review

Nyxoah’s 2026Q1 results revealed continued struggles with profitability despite revenue growth. The company reported revenue of $6.37 million, demonstrating steady demand for its products. However, the net income stood at a substantial loss of $-15.94 million, highlighting the high cost of operations and research. Gross profit was recorded at $3.64 million, indicating a healthy gross margin but insufficient to cover operating expenses. Consequently, EPS fell to $-0.37, underscoring the significant gap between top-line performance and bottom-line results. These figures suggest that while sales are improving, the path to sustained earnings remains steep and costly.

Additional News

In recent developments, Nyxoah has announced a strategic partnership with leading sleep therapy providers in the Asia-Pacific region to expand its distribution network. This move aims to accelerate patient access to its hypoglossal nerve stimulation technology in high-growth markets. Additionally, the company’s CEO, Jean-Luc Gervy, recently spoke at the International Conference on Sleep Medicine, emphasizing the growing clinical evidence supporting the efficacy of their treatment for obstructive sleep apnea. He highlighted that new real-world data presented at the conference demonstrates improved patient adherence rates compared to traditional CPAP therapies. Furthermore, Nyxoah has initiated a new clinical trial in North America to evaluate long-term outcomes for pediatric patients, marking the first time such a study is being conducted for this technology in children. The company also reported that its patent portfolio has been strengthened with new approvals in key European jurisdictions, securing intellectual property rights for its next-generation device designs. These activities reflect a dual focus on geographic expansion and scientific validation to support long-term commercial success.

Summary & Outlook

Nyxoah’s financial health shows improving revenue traction but persistent unprofitability, with Q1 losses narrowing slightly. Growth catalysts include successful Asia-Pacific partnerships and strong clinical data supporting market differentiation. However, risks remain high due to substantial operating expenses and the extended timeline to GAAP profitability. While the company is executing well on commercialization and regulatory fronts, the heavy cash burn limits near-term upside. The outlook is cautiously neutral; while long-term prospects are bullish due to the large addressable market and superior product efficacy, investors must tolerate continued volatility and losses. The stock is likely to remain sensitive to cash runway updates and clinical trial milestones rather than quarterly earnings beats.